Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds
A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid β peptides (Aβ) and/or with a changed ratio of levels of Aβ isoforms and/or with the formation of plaques containing amyloid β peptide (Aβ) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R 2 , R 3 , R 5 , R 6 , L1 and i are defined as in claim 1.
1. A compound selected from the group of formulas I.3a, I.3b, I.4a, I.4b
Y is —(SO 2 )—;
R 1 , R 3 , R 4 are each independently selected from the group consisting of H, F, Cl, Br, CN, CF 3 , C 1-4 -alkyl and C 1-4 -alkoxy; and
R 5 is selected from the group consisting of H, C 1-4 -alkyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkyl-C 1-3 -alkyl, phenyl and phenyl-C 1-3 -alkyl, wherein the phenyl ring of the phenyl or the phenyl-alkyl group may be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, CN, CF 3 , C 1-4 -alkyl, C 1-4 -alkylcarbonyl;
R 6 is H or C 1-4 -alkyl;
L1 is each independently selected from the group consisting of C 1-4 -alkyl, C 1-3 -alkoxy, F, Cl, Br, CN, NO 2 and CF 3 ;
L2 is each independently selected from the group consisting of C 1-4 -alkyl, F, Cl, Br, CN and CF 3 ;
i is 0, 1, 2, 3, 4 or 5;
j is 0, 1, 2 or 3;
m is 1;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein R 5 is selected from the group consisting of H, methyl, ethyl, cyclopropyl, phenyl and phenylmethyl, wherein the phenyl ring in the phenyl group or phenylmethyl group may be substituted with F, Cl, Br, C 1-4 -alkyl or C 1-4 -alkyl-carbonyl.
3. A compound according to claim 1 wherein the compound is selected from the formulas I.3.1a, I.3.1b
wherein the substituents R 1 , R 4 , L1 and L2 and the index i and j are defined as in claim 1 ,
or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
5. A compound selected from the formulas I.2.2a, I.2.2b
wherein
R 5 is selected from the group consisting of H, C 1-4 -alkyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkyl-C 1-3 -alkyl, phenyl and phenyl-C 1-3 -alkyl, wherein the phenyl ring of the phenyl or the phenyl-alkyl group may be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, CN, CF 3 , C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkylcarbonyl;
R 6 is H or C 1-4 -alkyl;
L1 is each independently selected from the group consisting of C 1-4 -alkyl, C 1-3 -alkoxy, F, Cl, Br, CN, NO 2 and CF 3 , with the proviso that L1 is not Cl in para-position if index i is 1 and R 5 is methyl;
i is 0, 1, 2, 3, 4 or 5;
or a pharmaceutically acceptable salt thereof.
6. A compound according to claim 5 wherein R 5 is selected from the group consisting of H, C 1-4 -alkyl, phenyl and phenyl-C 1-3 -alkyl, wherein the phenyl ring of the phenyl or the phenyl-alkyl group may be substituted with one or more substituents independently selected from the group consisting of F, Cl, Br, CN, CF 3 , C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkylcarbonyl.
7. A compound according to claim 5 of the formula